A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA

Fujisawa Healthcare, Inc0 个研究点目标入组 620 人开始时间: 2005年7月27日最近更新: 2014年10月7日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 620

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Informed consent of the patient or legally authorized representative, and HIPAA
•Authorization for U.S. sites, or equivalent privacy language as per national regulations, must be obtained prior to entry. Unconscious / incapable patients may be enrolled provided written informed consent is obtained from the legally authorized representative prior to enrollment.
•2. Patients must have candidemia or invasive candidiasis, documented by at least one typical clinical sign or symptom and confirmed by fungal culture and/or histology
•For candidemia or acute invasive candidiasis, a positive culture must be
•documented from a sample obtained no more than 96 hours prior to the first dose of study medication.
•For chronic invasive candidiasis, a positive culture within the last 4 weeks prior to
•randomization is acceptable provided the patient has findings of endophthalmitis
•or hepatosplenic lesions documented by radiographic imaging and has not received
•greater than two days of prior systemic antifungal therapy, as defined in exclusion
•criteria #9, within the last 7 days prior to randomization.
•- For invasive candidiasis, culture results may be pending at the time of enrollment if histology/cytology reveals yeast.
•- For candidemia, preliminary evidence of yeast (by staining and microscopy of
•the blood culture sample) is required to enroll a patient.
•- A confirmation of Candida species must be obtained within one week after enrollment.
•3. Patients may be of either gender. Females of childbearing potential must have a
•negative pregnancy test. A pregnancy test should be performed within 14 days prior
•to the first dose of study drug.
•4. Patients 18 years of age or older.
•5. Patients must have sufficient venous access to permit administration of study
•medication and monitoring of safety variables.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Patient is pregnant or nursing. Females of childbearing potential must avoid
•becoming pregnant while receiving study drug.
•2. Patients with a Child-Pugh Score > 9. For patients with no findings of ascites or encephalopathy and a total bilirubin < 2 mg/dL, the Child-Pugh score does not need to be calculated.
•3. Patients whose sole diagnosis is oropharyngeal and/or esophageal candidiasis and/or with positive cultures only of urine specimens, sputum specimens, bronchoalveolarlavage specimens or samples from indwelling drains.
•4. Patients with a history of allergy, hypersensitivity, or any serious reaction to the
•echinocandin class of antifungals.
•5. Patients previously enrolled into this study.
•6. Patients with a concomitant medical condition, whose participation, in the opinion of the Investigator and/or medical adviser, may create an unacceptable additional risk.
•7. Patients with a life expectancy of less than five days.
•8. Patients who have received an echinocandin within one month prior to study entry.
•9. Patients who have received more than two days of prior systemic antifungal therapy for the current infection.
•Daily dosing can not exceed the following: 1 mg/kg of body weight of
•amphotericin B, 5 mg/kg of a lipid amphotericin B formulation, 800 mg of
•fluconazole, 400 mg of itraconazole, or 12 mg/kg of body weight of voriconazole.
•Combination antifungal therapy is not allowed.
•Patients may have received prophylaxis with azoles or systemic amphotericin B
•products without time restrictions.
•10. Patients with yeast or mold-like infection other than invasive candidiasis or candidemia.
•11. Patients receiving cyclosporine.
•12. Patients known, at time of study entry or within 72 hours post randomization, to have Candida endocarditis, Candida osteomyelitis, or Candida meningitis.

研究者

发起方

Fujisawa Healthcare, Inc

相似试验

进行中（未招募）

不适用

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIAInvasive candidiasis or candidemiaMedDRA version: 7.0Level: PTClassification code 10042938

EUCTR2004-001491-39-ATAstellas Pharma US, Inc.620

进行中（未招募）

不适用

EUCTR2004-001491-39-CZAstellas Pharma US, Inc.620

进行中（未招募）

1 期

EUCTR2004-001491-39-GBAstellas Pharma US, Inc.620

进行中（未招募）

1 期

EUCTR2004-001491-39-ESFujisawa Healthcare, Inc620

招募中

3 期

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR 042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCERovarian canceradenocarcinoma10033283

NL-OMON54558TESARO, Inc.38